T he direct thrombin inhibitor dabigatran has recently been approved in the US as an alternative to warfarin for risk reduction in stroke and systemic embolism in patients with nonvalvular atrial fib rillation. Several studies assessing the risk of major bleeding complications have shown dabigatran to have a reduced amount of risk compared with other anticoagulants. 12, 14, 18, 21 However, the lack of guidelines, protocols, and an established specific antidote to reverse the anticoagulation effect of dabigatran potentially increases morbidity and mortality in patients with CHI. Confronted with this new problem, we reviewed our initial clinical experience.
between February 2011 and May 2011. Ground-level falls were placed into 2 separate categories: 1) falls from stairs or steps, sidewalk or curb, and escalator; and 2) falls from a standing or seated position. We divided these patients into 3 groups based on their anticoagulant therapy: dabigatran, warfarin, and NAC. Patient characteristics, comorbidities, mechanism of injury, ISS, GCS scores at admission and discharge, laboratory data, CT scan findings, results of neurological examinations, treatment modality variables, and survival status were obtained from our trauma registry.
All patients with CHI who were on warfarin were placed on a standardized reversal protocol similar to the revised protocol used by Ivascu et al. 6 Patients with evidence of an ICH on CT scans received an immediate transfusion of 2 U of type AB FFP, followed by another transfusion of 2 U of typespecific FFP. These patients also received vitamin K intravenous piggyback and an immediate neurosurgery evaluation. Due to the lack of an established protocol, there were variations in the treatment methods for the patients with CHI who were on dabigatran. The radiologist on call, who was blinded to both clinical findings and the patient's anticoagulant medications, interpreted the CT scan findings. All suspected hypertensive ICHs and nontraumatic SAHs were excluded from our study.
Statistical Analysis
Statistical analysis was conducted using IBM SPSS Version 20. The p values for categorical variables (sex, CT findings, associated medications, and deaths) were derived from the Fisher exact test, and for continuous variables (age, ISS, and GCS score) an independent-sample t-test was used. All p values were 2-tailed and values < 0.05 were considered to indicate statistical significance.
Results
Between February 2011 and May 2011, CHIs from ground-level falls were sustained by 5 patients while on dabigatran, by 15 patients on warfarin, and by 25 who were not on anticoagulants. Of the 5 patients on dabigatran, 4 fell from a standing and 1 fell from a sitting position. Of the 15 patients on warfarin, 14 fell from a standing position and 1 fell from stairs. Of the 25 patients who were not receiving anticoagulants, 24 fell from a standing position and 1 fell from a skateboard. Of the 5 patients in the dabigatran group, the mean age was 82 years (range 79-85 years), and the male/female ratio was 3:2. The mean age of the 15 patients in the warfarin group was 84 years (range 71-95 years), with a male/female ratio of 2:1. The 25 patients in the NAC group had a mean age of 75 years (range 19-93 years), with a male/female ratio of 1:1. The mean ISS score was 20 (range 4-25) in the dabigatran group, 16.5 (range 4-25) in the warfarin group, and 13.6 (range 2-30) in the NAC group. The dabigatran group had a mean GCS score of 14.6 at presentation, in the warfarin group the GCS was 14.6, and in the NAC group it was 14.2. Excluding deaths, the mean GCS scores at discharge were 14.3 in the dabigatran group, 14.5 in the warfarin group, and 14.8 in the NAC group. 
Discussion
Dabigatran etexilate is an oral prodrug that is rapidly converted by a serum esterase into a potent, direct, competitive inhibitor of thrombin. It is approved as an alternative to warfarin for risk reduction in stroke and systemic embolism in patients with nonvalvular atrial fibrillation. The kidneys excrete 80% of the standard given dose, and its serum half-life is 12-17 hours. The time to peak drug concentration occurs approximately 1.5-3 hours after oral administration, with the maximal effect on coagulation being within 2 hours.
14 Due to its predictable anticoagulation response dabigatran does not require routine anticoagulation monitoring, which can be seen as a major advantage over warfarin. Furthermore, dabigatran is not affected by changes in diet, and it has fewer drug-to-drug interactions compared with its counterpart warfarin. 18 The Randomized Evaluation of Long-term Anticoagulation Therapy (RELY) trial demonstrated a reduction in the risk of stroke when comparing warfarin to dabigatran: from 1.57% (warfarin) to 1.01% (dabigatran). Intracranial bleeding was reduced from 0.74% (warfarin) to 0.30% (dabigatran), and life-threatening bleeding from 1.80% (warfarin) to 1.45% (dabigatran), without any significant change in overall major bleeding-3.36% (warfarin) to 3.11% (dabigatran). Life-threatening bleeding was a subcategory of major bleeding that consisted of fatal bleeding, symptomatic intracranial bleeding, bleeding with a decrease in the hemoglobin level of at least 50 g/L, or bleeding requiring transfusion of at least 4 U of blood or inotropic agents, or necessitating surgery. Major bleeding was defined as a reduction in the hemoglobin level of at least 20 g/L, transfusion of at least 2 U of blood, or symptomatic bleeding in a critical area or organ. 2 Total mortality rates were also lowered from 4.13% per year on warfarin to 3.64% for patients on dabigatran. 21 All these benefits make dabigatran an attractive alternative to its anticoagulant predecessor.
Unintentional falls are the leading cause of injuryrelated deaths and emergency department visits in the elderly population in the US.
1 As the population ages, more injuries from falls will be seen in the near future. A recent report found that falls from standing account for 27.3% of trauma admissions and are the second greatest consumer of hospital and ICU days. For patients 65 years of age and older, falls accounted for 43% of all injuries.
1 Mem- bers of the elderly population also have a worse prognosis compared with the younger population, demonstrated by a mortality rate of 24% after suffering a traumatic brain injury, compared with 12.8% in the nonelderly population. 16 The elderly also experience greater morbidity, as illustrated by longer hospital stays, worse functional outcomes, lower discharge GCS scores, and lower functional independence measure scores compared with their younger counterparts. 9, 10 To complicate this matter even further, the prevalence of atrial fibrillation is strongly dependent on age, indicating that the use of oral anticoagulation therapy will probably substantially increase due to the projected aging of the US population. 3, 5 When comparing warfarin to dabigatran, the health care provider must remember that warfarin's anticoagulant effects can be rapidly reversed. Options include vitamin K, FFP, cryoprecipitate, PCCs (a preparation of concentrated forms of clotting factors II, VII, IX, and X that is used specifically to replace the factors that are inactivated by warfarin), factor IX complex, and rFVIIa (Novoseven). 7, 11, 17 The best approach to warfarin reversal is controversial, and there are few published studies to guide best practice. The general consensus is that major or life-threatening bleeding requires rapid and complete warfarin reversal. 4, 8 The efficacy coupled with the near universal availability of FFP in most countries results in FFP becoming a dominant tool for urgent warfarin reversal. Ivascu et al. 6 found that the implementation of an aggressive reversal protocol was found to reduce time in triage (31 minutes vs 14 minutes), and the time to head CT scan from more than 2 hours to approximately 40 minutes. This reduced the time to initiation of reversal from more than 4 hours to less than 2 hours. More importantly, the death rate was decreased from 50% to 10% after implementing an aggressive warfarin protocol.
The combination of dabigatran's increasing popularity and our nation's aging baby boomer society leads to a potential dilemma. A specific agent and/or protocol for reversing the effects of dabigatran is currently unavailable in published clinical data. 20 Our review of the current literature and preclinical studies suggests that future management options may include the use of activated charcoal, hemodialysis, and administration of rFVIIa and/or PCC. 12, 20 On the basis of the mean concentration differences, the mean fraction of dabigatran removed by dialysis was 62% at 2 hours and 68% at 4 hours. 15 In their own pharmaceutical insert, the manufacturer (Boehringer Ingelheim Pharmaceuticals) suggests the use of FFP and/or packed red blood cells. However, although this may be a part of the usual treatment for bleeding, there is no clinical experience or evidence supporting the use of plasma products as a means to reverse the anticoagulant effect of dabigatran. 20 Findings in healthy volunteers and ex vivo data suggest that rFVIIa antagonizes the anticoagulant effects of dabigatran by initiating homeostasis at sites of bleeding by directly activating thrombin on the surface of platelets in the absence of tissue factor. 19, 20 As a result, this agent may have a potential off-label use for reversing anticoagulation in patients on dabigatran who sustain ICHs. 12 Another consideration is activated PCCs (Fieba VH), which have shown significant reductions in bleeding times in ex vivo models, and complete reversal of dabigatran-inhibited thrombin potential by using human plasma in an in vitro study. 13, 19 To our knowledge, this is the first study to bring to light this dilemma. In our case series of 5 patients presenting with CHIs while on dabigatran, the patients had no significant difference in demographic or clinical characteristics with regard to sex, age, ISS, GCS scores, comorbidities, associated medications, mechanism of injury, or type of ICH. Despite these similarities between both groups, our analyses showed a statistically significant difference in terms of injury progression seen on CT scans (p = 0.03, Fisher exact test) and a clinically significant higher mortality rate in the dabigatran group (p = 0.05, Fisher exact test; Table 1 ). 6 As already discussed, the benefits and application of an anticoagulation reversal protocol is key to improving treatment and outcome in the case of warfarin. The lack of an established protocol and a specific antidote led to a substantial variance at our institution in the treatment of the patients on dabigatran. None of the 5 patients received activated charcoal. Only 4 of the 5 patients received rFVIIa, with a mean transfusion start time of 118.5 minutes (range 35-132 minutes). Four of 5 patients received transfusions of FFP, 3 of 5 received platelets, and 2 of 5 received FFP and platelets (Fig. 1 ). Only 2 of 5 patients received dialysis, with a mean start time of 441 minutes (range 255-627 minutes) after presentation. All 5 patients had repeat CT scans during reversal, 4 of which showed new or expanding hemorrhages. This demonstrates dabigatran's devastating potential predicament. On review of our treatment approach, a great deal of variance was observed in regard to the time and type of treatment received. Because of these data, and the literature cited earlier, our institution is establishing a reversal protocol for the treatment of patients on dabigatran presenting with CHI (Fig. 2) .
Conclusions
Classic anticoagulants, such as warfarin, have reasonable efficacy and specific antidotes, but also have undesirable features. Newer anticoagulants such as dabigatran were developed to overcome these undesirable features, but in return do not have a specific reversal protocol. As the use of dabigatran becomes more ubiquitous in the population with atrial fibrillation, it is critical for physicians involved in the care of patients with CHI to be aware of an elevated mortality rate in these patients if no treatment protocol or guideline is in place. The intention of this paper is not simply to bring to light the higher mortality rate associated with CHI in patients on dabigatran, but to the fact that physicians are not prepared to deal with it. In an attempt to improve efficacy and safety in our treatment approach, we will soon implement a reversal management protocol for patients with CHI on dabigatran at our institution in a prospective study (Fig.  2) . This study was limited by the small population size, its retrospective design, having no standardized method to evaluate the hemorrhage blood volume, and the fact that patients were on multiple other anticoagulants, potentially altering their outcomes.
